Successful imatinib and arsenic trioxide combination therapy for sudden onset promyelocytic crisis with t(15;17) in chronic myeloid leukemia.
Kashimura
Makoto
M
Ohyashiki
Kazuma
K
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage; D001549:Benzamides; D001752:Blast Crisis / Q000188:drug therapy* / Q000235:genetics; D002884:Chromosomes, Human, Pair 15 / Q000235:genetics*; D002886:Chromosomes, Human, Pair 17 / Q000235:genetics*; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D010087:Oxides / Q000008:administration & dosage; D010879:Piperazines / Q000008:administration & dosage; D011379:Prognosis; D011743:Pyrimidines / Q000008:administration & dosage; D014178:Translocation, Genetic / Q000235:genetics*
D001152:Arsenicals; D001549:Benzamides; D010087:Oxides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D000077237:Arsenic Trioxide